NICE guideline on endometriosis diagnosis and management

That this House urges the National Institute for Health and Care Excellence (NICE) to review and update guideline NG 73 on endometriosis diagnosis and management and to begin the process of doing so before the end of 2022; notes that endometriosis affects one in ten women and those assigned female at birth from puberty to menopause although the impact may be felt for life; further notes that lengthy diagnosis times and lack of treatment options can negatively impact both the physical and mental health of those with endometriosis; recognises that while NICE guideline NG 73 outlines a baseline of care for endometriosis there are gaps in it that need addressing, including but not limited to improving pain management for pharmacological and non-pharmacological approaches, endometriosis outside the pelvic cavity and mental health support; highlights that the European Society of Human Reproduction and Embryology (ESHRE) published a new updated European guideline on endometriosis on 2 February 2022, which includes extensive review of recent research and other evidence and makes some new recommendations not covered by NG 73; notes that NICE usually reviews guidelines every five years and in September 2022 it will be five years since the guideline was published and that it remains unamended since publication; and calls on the Department of Health and Social Care to ask NICE to update guideline NG 73.